FDA Expands Indication for Urticaria Drug to Treat Symptomatic Dermographism

(MedPage Today) -- The FDA expanded the indication of the Bruton's tyrosine kinase (BTK) inhibitor remibrutinib (Rhapsido) to treat symptomatic dermographism, the most common form of chronic inducible urticaria, Novartis announced Thursday. The...